ALMOTAN 6.25MG TABLET 4'S

No, ALMOTAN 6.25MG TABLET 4'S is neither a narcotic nor does it have abuse potential. It is an antimigraine agent which belongs to a class of compounds known as selective serotonin receptor agonists.

The maximum daily dose is two tablets within 24 hours. However, a gap of at least 2 hours between first and second dose needs to be maintained.

ALMOTAN 6.25MG TABLET 4'S may take 2-3 hours to show its effect, wait for it to work. If still there is no considerable improvement then you can take NSAIDs (e.g., ibuprofen), but do not take additional triptans for relief.

ALMOTAN 6.25MG TABLET 4'S is not used for the prevention of migraine attacks or cluster headaches. However, it should only be used in cases where a clear diagnosis of migraine has been established.

ALMOTAN 6.25MG TABLET 4'S is safe if you are taking this medicine for four migraine episode in a 30-day period. However, it has not been established that the medicine is safe if used for treating an average of more than four migraine episodes in a 30-day period.

Before taking ALMOTAN 6.25MG TABLET 4'S, you should inform your doctor if you have a heart disease or any risk factor associated with it (e.g., high blood pressure, diabetes, smoking, family history of heart disease, men over 40 years of age, or a postmenopausal women), mild to moderate liver disease, or severe kidney disease. The doctor should be informed if your headache is associated with dizziness, difficulty in walking, lack of coordination, or weakness in the leg and arm. Along with that, it is important to inform your doctor if you are taking medicines such as selective serotonin reuptake inhibitors (SSRIs) (e.g., sertraline, escitalopram oxalate, and fluoxetine) or serotonin norepinephrine reuptake inhibitors (SNRIs) (e.g., venlafaxine), and duloxetine for depression.

Yes, Migraines may run in families. Migraines occur more often in women than men. It has been observed that some women, but not all, have fewer migraine attacks when they are pregnant.

Almotan 6.25 contains almotriptan, a triptan medicine used for the acute treatment of migraine attacks with or without aura. It is intended to relieve headache pain and associated symptoms such as nausea, sensitivity to light (photophobia), and sensitivity to sound (phonophobia). It is not used to prevent migraines or to treat other types of headache.

Almotan 6.25 works by stimulating specific serotonin (5‑HT1B/1D) receptors in blood vessels and nerve endings in the brain. This leads to constriction of dilated cranial blood vessels and reduces the release of inflammatory neuropeptides involved in migraine. Together, these actions help decrease headache pain and other migraine symptoms.

Almotan 6.25 is generally most effective when taken as soon as the migraine headache phase begins. Some people may be advised to take it after the headache starts rather than during the aura phase. The exact timing and whether a repeat dose is allowed depend on your doctor’s instructions and the official product information. Do not exceed the maximum number of doses or treatment days recommended by your healthcare provider.

No. Almotan 6.25 is not a preventive migraine medicine and should not be taken daily to stop attacks from occurring. It is intended only for the acute treatment of individual migraine attacks. Using triptans or other acute migraine medicines too frequently can lead to medication‑overuse headache and may worsen your overall headache pattern. If you need treatment for attacks very often, speak with your doctor about preventive options.

People with liver impairment may have reduced ability to clear almotriptan from the body, which can increase the risk of side effects. In mild to moderate liver disease, dose adjustments or limits on maximum daily use may be recommended according to local prescribing information. In severe liver impairment, triptans, including almotriptan, may be contraindicated or used only with extreme caution. You must inform your doctor about any history of liver disease so they can decide whether Almotan 6.25 is appropriate for you and how it should be used.

Almotriptan is partly eliminated through the kidneys, so people with reduced kidney function may be more exposed to the medicine. In mild to moderate kidney impairment, your doctor may adjust the dosing schedule or maximum daily dose based on official product guidance. In severe kidney disease, use may be restricted or avoided. Always tell your healthcare provider if you have any degree of kidney impairment, are on dialysis, or have a history of kidney disease before using Almotan 6.25.

Data on almotriptan use in pregnancy are limited. Triptans are generally used in pregnancy only when clearly needed and when potential benefits outweigh possible risks to the fetus. If you are pregnant, think you might be pregnant, or are planning to become pregnant, discuss all migraine treatment options with your doctor. Do not start or continue Almotan 6.25 in pregnancy without specific medical advice and a careful risk–benefit assessment.

Almotriptan may pass into breast milk to some extent, although detailed data are limited. Your doctor will weigh the benefits of treating your migraine against any potential risk to the nursing infant. In some cases, you may be advised to avoid breastfeeding for a certain period after taking a dose, or to use an alternative treatment with more established safety data in lactation. Always consult your healthcare provider before using Almotan 6.25 while breastfeeding.

Almotan 6.25 can cause side effects such as dizziness, drowsiness, fatigue, or visual disturbances in some people. In addition, migraine itself can impair concentration and reaction time. You should avoid driving, operating machinery, or performing tasks that require full alertness until you know how Almotan 6.25 affects you. If you feel dizzy, sleepy, or unwell after taking it, do not drive or use heavy machinery.

Alcohol can trigger or worsen migraine attacks in some individuals and may increase drowsiness or dizziness when combined with medicines like almotriptan. While there is no specific interaction that universally forbids alcohol, it is generally advisable to avoid or limit alcohol when you are prone to migraines or when you are taking Almotan 6.25. If you choose to drink, do so cautiously and be aware of how your body responds.

You should not take Almotan 6.25 if you have a known allergy to almotriptan or any of the excipients in the product. Signs of an allergic reaction can include rash, itching, swelling of the face, lips, tongue, or throat, difficulty breathing, or severe dizziness. This can be serious and requires immediate medical attention. Inform your doctor about any previous drug allergies, including to other triptans, before starting Almotan 6.25.

Almotan 6.25 is generally not recommended for people with a history of heart attack, certain types of angina, significant coronary artery disease, peripheral vascular disease, uncontrolled high blood pressure, stroke or transient ischemic attack, or certain serious rhythm problems. It is also usually avoided in severe liver or kidney impairment and in people with specific rare types of migraine such as hemiplegic or basilar migraine. Children and adolescents may have age‑specific restrictions depending on local guidelines. Your doctor will review your medical history and risk factors before prescribing this medicine.